Podcasts about laval university

The ‘bone collector' caterpillar covers itself with body partsIt's like something from a horror movie. A creeping, carnivorous creature that in a macabre attempt at disguise and protection, covers itself with the dismembered remains of dead insects. This super-rare caterpillar is one of the strangest insects in the world. It lives on spider webs inside of trees and rock crevices in a 15 square kilometre radius on the Hawaiian island of O'ahu. Daniel Rubinoff, from the University of Hawaii Insect Museum, found about 62 of these caterpillars over the past 20 years. Their research was published in the journal Science. If a dolphin pees in the water, does anybody know it?Researchers observing river dolphins in Brazil were first surprised to see the animals turning on their backs and urinating into the air, and then further amazed to see other dolphins sampling the falling stream. The Canadian and Brazilian team, led by Claryana Araújo-Wang from the CetAsia Research Group, believe this aerial urination may be a way to communicate dominance among males. The research was published in the journal Behavioural Processes.How the snowball Earth made life bloom on our planet700 million years ago our planet was frozen from pole to pole during a period known as snowball Earth. Glaciers at that time scoured deep into the continents below like a giant bulldozer, grinding the rock into fine sediments. In a new study in the journal Geology, scientists found that as the glaciers melted, a lot of that loose material was injected very rapidly into the oceans. Branden Murphy, from St. Francis Xavier University, said this chemical cocktail fertilized the oceans, and set the stage for rise of multicellular complex life on Earth.  How a team of microbiologists use cars to sample air across the countryUnderstanding the distribution of bacteria that might be a concern for human or animal health across an entire country is a huge job. But a team from Laval used a very clever shortcut to gather their data. They collected car air filters from vehicles across the nation, and looked in them to see what they sucked up. They found regional differences in the antimicrobial resistance genes specific to the agricultural activities and environmental factors at each location. Paul George, from Laval University, was the lead researcher on the study published in the journal Environmental DNA.Albertan obsidian artifacts are the end point of a widespread Indigenous trade networkObsidian — volcanic glass used to make super-sharp tools — is found as artifacts from chips to blades to arrowheads at hundreds of sites across the Rockies of Alberta and B.C., dating back thousands of years. However, there are no volcanos in the area so archaeologists are using this volcanic glass to chart Indigenous trade routes through North America. New research, led by Timothy Allan of Ember Archeology, has traced the obsidian's point of origin to a site nearly 1,000 kilometres away, suggesting the material travelled over long distances and passed through many hands. The research was published in the Journal of Field Archaeology.Do his gills ring a bell? Fish can recognize humansScientists at a Mediterranean research station kept noticing that particular fish would follow them around whenever they would try and do experiments. To find out if the fish were actually capable of recognizing individual humans, a team from the Max Planck Institute of Animal Behavior in Germany decided to turn this annoying behaviour into a scientific experiment. They found that the fish were indeed capable of remembering which humans had shared tasty treats in the past. The research was published in the journal Biology Letters.

This episode features Prof. Yves Desjardins PhD from Laval University in Canada. Prof. Desjardins, an agrologist by training, explains that polyphenols are metabolites synthesized by plants and present in the plant foods we consume. When humans consume polyphenols, we absorb a small fraction (around 5%) of them in the upper gastrointestinal tract, but most of […] The post Interactions of polyphenols in the gut, with Prof. Yves Desjardins PhD appeared first on International Scientific Association for Probiotics and Prebiotics (ISAPP).

This EP fetures Jonathan Pelletier Ouellet. Jo as he is known by most is a Strength and Conditioning Coach and Physiotherapist with over 15 years of experience in the field. He specializes in athlete reconditioning following traumatic and chronic injuries.Since 2008 he's been a key member of Freestyle Canada.  From 2009 to 2018 he traveled with the Canadian Freestyle Aerials Team as their Strength and Conditioning Coach, Physiotherapist, and Lead Integrated Support Team (IST) member. During this period, Jonathan had the privilege of working at three Olympic Games: Vancouver 2010, Sochi 2014, and Pyeongchang 2018.In addition to this role, Jonathan began working with Speed Skating Canada Long Track in 2018, where he continues to serve at the Quebec City training center. Jonathan also holds the role of Paramedical Lead for the team based in Quebec City.He is also a passionate educator, lecturing in both the Kinesiology and Physiotherapy departments at Laval University. Additionally, he provides continuing education in kinesiology and physiotherapy, focusing on athlete reconditioning post-traumatic and chronic injuries. Please enjoy the ride!If you liked this EP, please take the time to rate and comment, share with a friend, and connect with us on social channels IG @Kingopain, TW @BuiltbyScott, LI+FB Scott Livingston. You can find all things LYM at www.LYMLab.com, download your free Life Lab Starter Kit today and get busy living https://lymlab.com/free-lym-lab-starter/Please take the time to visit and connect with our sponsors, they are an essential part of our success:www.ReconditioningHQ.comwww.FreePainGuide.com

Paul George is an assistant professor at Laval University in Quebec. He asked people from around the country to send in air filters from their cars so he could study the amount of antimicrobial resistant bacteria in different regions. The Morning Show's Jonny Hodder spoke with Paul to find out more.

Thanks for checking out our first regular episode of On The Line, The Line's latest podcast offering. Each week, On The Line will bring you an extended conversation with Matt Gurney or Jen Gerson and a guest — or guests! — that can speak with authority on whatever is in the news. And this week, well. Like, look around. OMG.The week's episode of On The Line is brought to you by the Motion Picture Association of Canada. For decades, Ottawa controlled what is “Canadian” and what isn't when it comes to series and movies available to Canadians. The rules are out of date and costing Canadians opportunities. It's time for Ottawa to focus on helping Canadian film and TV workers, and encourage efforts to showcase Canada. To learn more visit https://www.mpa-canada.org/All kidding aside, and we suspect our viewers and listeners will understand, we had to change our plans like nine times before recording this, trying to keep up with developments. But we stuck the landing! Our first guest is Stephen Gordon, a professor of economics at Laval University. He joins this week's host Matt Gurney to talk about what Trump's tariff war would mean for Canada. How it would hurt. How Canada would adapt. How you can adapt. And also what could happen if this resumes and escalates. It's not great news. But it might not be as bad as you fear.For clarity: when we recorded this, the tariffs were still happening, but we knew there was a chance they'd be lifted. There was a lot going on! We treated it as something that would happen, but Stephen also told us why even the U.S. would be keen to avoid them …This week's episode is also brought to you by the Métis Nation of Ontario. The Métis in what is now Ontario were not just traders or voyageurs — they were strategists and warriors ready to defend their lands and water from invaders. Their contributions in the War of 1812 shaped the borders of a future Canada. To learn more, go to https://www.ontariometisfacts.com/Our next guest is P.J. Fournier, creator of 338Canada. (Check out his main page at 338Canada.com, and also his newsletter at 338Canada.ca.) P.J. gives us an update on federal polling, and addresses why some of it seems so wonky. He also gives us an update on two provinces — Ontario already has an election underway, and next door in Quebec, an unpopular premier is no doubt watching to see if his pal Doug pays a price for calling an early vote ... As always, like and subscribe and check out our main page at ReadtheLine.ca. And we'll see you next week for the next installment of On The Line.

Rita-Rose Gagné is the CEO of Hammerson plc, an owner, operator and developer of prime, urban real estate in some of the fastest growing cities in the UK, Ireland and France.She joined the company in 2020 to develop and spearhead the strategic transformation of the business.She brings extensive experience in real estate investment - and global property markets - combined with strong strategic, operational leadership and financial management skills.Prior to joining Hammerson, Rita-Rose was President of Growth Markets at Ivanhoé Cambridge, responsible for over $8bn of real estate assets, platforms and a development pipeline across Asia Pacific and Latin America, covering logistics, retail, mixed use, office and residential.Rita-Rose holds a Bachelor of Law from Laval University as well as an MBA from McGill and HEC Montréal.

Musicians and athletes might sometimes appear to exist in very different cultures. And yet, the single-minded focus, thousands of hours of practice, and high training loads on their musculoskeletal systems mean that musicians and athletes probably have more in common than they have differences. At least from a musculoskeletal rehabilitation perspective. Today's guest is Marianne Roos - a former clarinetist and forever musician-at-heart, who now practices as a physiotherapist and conducts her PhD research from Laval University, Canada. Marianne explains the physical and psychological demands of orchestra performance on the musician's body, and shares the results of her PhD research in developing programmes to reduce musculoskeletal injuries among orchestra musicians. ------------------------------ RESOURCES Barriers and facilitators to implementing rehabilitation and wellness programs for orchestral musicians: https://pubmed.ncbi.nlm.nih.gov/33853373/ Workplace injury prevention and wellness program for orchestra musicians: https://www.jospt.org/doi/10.2519/jospt.2024.12277

The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA. It's too bad we at Reefer MEDness don't know anything about microRNA. But wait…We do! Hilal Kalkan, a post-doc at Laval University, talks to us about how microRNA and cannabinoid receptors are involved in the side effect of a common cholesterol medication. Come dive deep into the molecular workings of the endocannabinoid system with us!Hilal Kalkan - LinkedInDysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin, Hilal Kalkan et al. - Paper in Cell Death and Disease(Yes we got a SOCAN membership to use this song all legal and proper like)Music by:Tuğba Yurt - Benim O -YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

ChrysaLabs: https://www.chrysalabs.com/Today's episode features Sam Fournier, CEO and co-founder of ChyrsaLabs. I had the chance to briefly meet Sam at World AgriTech. Thank you to Sachi Desai and the Bayer team for the intro. And when I heard what they were doing, I immediately asked if he'd ever be willing to come on the podcast. This idea of providing real time soil information on nutrients has been tried before and as far as I know the tech just hasn't worked. But ChrysaLabs has been at this since 2018 and have a track record of reliably providing this information, which is something that I think is super exciting for the future of agriculture. I wanted to ask more though about how the tech works, how affordable it could be for farmers and agronomists, what impact this could have on management decisions, and where Sam wants to take the company from here. For some background: Prior to founding ChrysaLabs in 2018, Sam held strategic positions in the development of smart cities implementation projects, electric recreational vehicles manufacturing and electric vehicle sustainable power plant solutions. He holds a B.A. in political Science from Sherbrooke University and an MBA from Laval University, and is driven by his vision for a more sustainable agriculture ecosystem.

In today's episode, host Tyler Chisholm is joined by Stéphane Hamel, teaching fellow in the department of marketing at Laval University, to discuss the collision of data privacy and digital marketing. With over two decades of experience in data analytics and privacy, Stephane brings a wealth of knowledge to the table. He explores the hidden costs customers bear, the false security metrics like views and clicks can create, and why many businesses struggle to assess the actual value of their advertising spend.This episode is brought to you by clearmotive marketing. When it comes to marketing that truly matters to your business, clearmotive is your go-to partner. With a proven track record of more than 15 years, they understand what makes your business tick. Learn more at https://www.clearmotive.ca and discover how clearmotive can help your marketing thrive.We're on social media! Follow us for episodes you might have missed and key insights on Western Canada directly on your feeds.Instagram: https://www.instagram.com/collisionsyycLinkedIn: https://www.linkedin.com/company/collisions-yycYouTube: https://www.youtube.com/@collisionsyycWebsite: https://www.collisionsyyc.comThank you for tuning into Collisions YYC!Remember to subscribe and follow us on Spotify and Apple Podcasts so you never miss an episode.If you loved the episode, please leave us a 5-star review and share the show with your friends! These things really help us reach more potential fans and share everything that's amazing about Western Canada.We sincerely appreciate your support of our local podcast.Host links:Tyler's website: https://www.tylerchisholm.comTyler's LinkedIn: https://www.linkedin.com/in/tylerchisholmGuest links:Stéphane Hamel's LinkedIn: https://www.linkedin.com/in/shamelLaval University's Website: https://www.ulaval.caLaval University's LinkedIn: https://www.linkedin.com/company/universite-lavalLaval University's Twitter: https://www.twitter.com/universitelavalLaval University's Facebook: https://www.facebook.com/ulaval.ca/Laval University's YouTube: https://www.youtube.com/ulavaltvCollisions YYC is a Tyler Chisholm original production // Brought to you by clearmotive marketing

Last night, Tuesday, October 15th, at 6 pm on The Brian Crombie Hour I interviewed diaMentis executives. Watch the full episode: https://youtu.be/llifXsLQ-1E. ALL my podcasts and videocasts can be accessed any time on my web site www.briancrombie.com which holds repository of all my shows. Founded in Quebec City in 2015, diaMentis has developed an innovative technology that uses retinal biomarkers to diagnose mental health disorders. Their primary focus is on conditions such as schizophrenia and bipolar disorder, with the aim of securing FDA "Breakthrough" designation for their diagnostic tool. Leveraging research from Laval University, diaMentis is dedicated to creating cutting-edge solutions that aid in the diagnosis of mental health conditions. The Brian Crombie Hour airs 6:00 pm nightly. Please subscribe to my YouTube channel: https://bit.ly/2Oioec8. Stream, listen, like, watch and share. Thank You!

Tonight, Tuesday, October 15th, at 6 pm on The Brian Crombie Hour I interview diaMentis executives. Watch the full episode: https://youtu.be/llifXsLQ-1E. ALL my podcasts and videocasts can be accessed any time on my web site www.briancrombie.com which holds repository of all my shows. Founded in Quebec City in 2015, diaMentis has developed an innovative technology that uses retinal biomarkers to diagnose mental health disorders. Their primary focus is on conditions such as schizophrenia and bipolar disorder, with the aim of securing FDA "Breakthrough" designation for their diagnostic tool. Leveraging research from Laval University, diaMentis is dedicated to creating cutting-edge solutions that aid in the diagnosis of mental health conditions. The Brian Crombie Hour airs 6:00 pm nightly. Please subscribe to my YouTube channel: https://bit.ly/2Oioec8. Stream, listen, like, watch and share. Thank You!

The days are getting shorter, the temperatures are becoming chilly, and the leaves are turning beautiful shades of red, yellow and orange. But what's behind the tree's yearly transformation, and how does climate change play a role? The CBC's Colleen Connors spoke with Loïc D'Orangeville, associate professor of forest ecology and restoration at Laval University.

Welcome to the Arete Coach Podcast, episode 1186, hosted by Severin Sorensen. In this enlightening episode titled "On Being Grateful, Generous, and Relevant," we are honored to have Louis-Samuel Jacques, a TEC Canada Master Chair, CEO Coach, and Speaker with TEC Canada and Vistage Worldwide. Recorded via Zoom on July 1st, 2024, this conversation delves into Jacques' philosophy of gratitude, generosity, and relevance in the realm of executive coaching. Renowned for his expertise in facilitating high-value conversations with CEOs, entrepreneurs, and business leaders, Louis-Samuel Jacques helps them navigate major decisions, ambitions, challenges, and opportunities. This episode offers valuable insights into Jacques' approach to empowering leaders and creating impactful coaching relationships. Louis-Samuel Jacques, a TEC Canada Master Chair, CEO Coach, and Speaker with TEC Canada and Vistage Worldwide, transitioned from a background in agri-food and environmental economics consulting to management consulting before finding his passion in executive coaching. Since 2018, he has served as a TEC Canada Chair, building five TEC Canada groups and engaging weekly with 30 to 50 CEOs, entrepreneurs, and business leaders. His exceptional performance earned him the Rookie of the Year award in 2020 and the prestigious title of TEC Canada Master Chair. Jacques holds an MBA from Laval University and is known for his keen observation skills and ability to identify universal principles driving success and freedom. His life purpose centers on empowering leaders to create the best places to live on earth, whether in one's own mind and body, home, workplace, community, or country. In this insightful episode of the Arete Coach Podcast, Louis-Samuel Jacques shares his inspiring journey from consultant to coach. With a background in economics and management consulting, Jacques found his true calling in empowering leaders through high-value conversations. His transition into coaching was not without challenges, as he recalls, "Launching a group takes three months. It takes three months, but only when you understand how to do it." This experience taught him the importance of patience and persistence in building effective leadership groups. Jacques emphasizes clarity over knowledge in his coaching approach, stating, "My north star is clarity. It's not showing up as being intelligent or knowledgeable or whatever." This philosophy guides his interactions with clients, focusing on creating an environment where leaders can thrive and make impactful decisions. He reflects on his personal growth as a coach, admitting, "It's not about me. I can easily be in the way of clarity for my members." This realization has shaped his coaching style, prioritizing being present and asking powerful questions rather than providing ready-made solutions. Throughout the interview, Jacques reveals his daily mantra: "Every morning I wake up and I tell myself, I remind myself that I want to be grateful. I want to be generous and relevant," which encapsulates his approach to life and coaching. This mindset has profoundly influenced his work, as he aims to empower leaders to create the best places to live on earth, whether in one's own mind, workplace, or community. Jacques views each day as a gift and an opportunity to make a positive impact, reflecting, "To me, every day is not a miracle, but is a gift and I have nothing to lose." His passion for helping others and his commitment to personal growth make Louis-Samuel Jacques a compelling figure in the world of executive coaching, offering valuable insights for both aspiring and experienced coaches alike. The Arete Coach Podcast seeks to explore the art and science of executive coaching. You can find out more about this podcast at aretecoach.io. This interview for this episode was recorded on July 1, 2024 via Zoom Video. Copyright © 2024 by Arete Coach™ LLC. All rights reserved.

EN : In this episode of Seeing Clearly, Mohamed Gemae and Anas Abu-Dieh (Eye Curriculum Ambassadors) speak with Dr. Emmanuelle Chalifoux, a strabismus specialist and program director at Laval University. This is the fifth and final episode of our French mini-series, "Vision Claire".   Dr. Chalifoux completed her medical degree at the University of Sherbrooke and her residency at Laval University. She then went on to complete subspecialty training in strabismus at McGill under the supervision of Dr. Michael Flanders. Today, she continues to practice general ophthalmology, and is a strabismus specialist at the Centre Hospitalier Universitaire de Québec (CHUQ). Additionally, Dr. Chalifoux is the director of the ophthalmology residency program at Laval University. Within her current role, she remains heavily involved in resident education and resident well-being.    In this episode, we discuss: Dr. Chalifoux's journey in ophthalmology What a "Week in the Life" of Dr. Chalifoux looks like What distinguishes the program at Laval University Advice for medical students/residents People who have inspired her in life! Check out our website: www.eyecurriculum.com Follow us on Instagram: www.instagram.com/EyeCurriculum Follow us on Twitter: www.twitter.com/EyeCurriculum FR : Dans cet épisode de Seeing Clearly, Mohamed Gemae et Anas Abu-Dieh (ambassadeurs de Eye Curriculum) discutent avec Dre Emmanuelle Chalifoux, spécialiste en strabisme et directrice de programme à l'Université Laval. Ceci est le cinquième et dernier épisode de la mini-série Francophone, “Vision Claire”. Dre Chalifoux a complété ses études en médecine à l'Université Sherbrooke et sa résidence à l'Université Laval. Ensuite, elle a complété une sous-spécialisation en strabisme à McGill sous la supervision du Dr Michael Flanders. Aujourd'hui, Dre Chalifoux est spécialiste en strabisme au Centre Hospitalier Universitaire de Québec (CHUQ). Elle continue aussi à pratiquer l'ophtalmologie générale. De plus, Dre Chalifoux est directrice du programme de résidence en ophtalmologie à l'Université Laval. Elle est très impliquée dans l'éducation et le soutien des résidents du programme d'ophtalmologie.  Dans cet épisode, nous abordons : Le parcours de Dre Chalifoux en ophtalmologie À quoi ressemble une "Semaine dans la vie" de Dre Chalifoux Ce que distingue le programme de l'Université Laval Des conseils pour les étudiants en médecine/résidents Des personnes qui l'ont inspiré dans sa vie!

A miniseries covering social work in Lebanon, dialogues between different generations of social workers. Tonight's guest is Hyam Hahi. - Over 40 years of experience in social work, primarily in academia. - Holds a BA in social work from Saint Joseph University (1971) & MA in social work from Laval University in Quebec, Canada (1984). Hosted by social worker Aimee Ghanem - founder of Sworld. Audio version available on The Beirut Banyan podcast. We extend our thanks to CEREC (www.thecerec.org) for providing the studio. The opinions expressed in this video are those of the participants and do not necessarily reflect the views of the platform. Don't forget to like the video, subscribe to the channel, and hit the bell icon to receive updates on all our new developments and insights. سلسلة فيديوهات قصيرة تتضمن حوارات بين مختلف الأجيال من العمال الاجتماعيين، حول العمل الاجتماعي في لبنان. باستضافة ايمي غانم مؤسسة Sworld النسخة الصوتية متوفرة على بودكاست Podcast the Beirut Banyan ضيوف حلقة الليلة: هيام سماحة قاعي أكثر من 40 سنة خبرة في العمل الاجتماعي أبرزها في المجال الأكاديمي حائزة على إجازة في الخدمة الاجتماعية من جامعة القديس يوسف (1971) وعلى ماستر في الخدمة الاجتماعية من جامعة لافال في الكيبيك - كندا (1984) نتقدم بجزيل الشكر لـwww.thecerec.org CEREC لتقديم الاستوديو الآراء الواردة في هذا الفيديو هي آراء الأشخاص المشاركين ولا تعكس بالضرورة وجهات نظر المنصة. لا تنسى الإعجاب بالفيديو، والاشتراك في القناة، وتفعيل زر الجرس ليصلك كل جديد. Social Media links: •⁠ ⁠https://www.youtube.com/channel/UC4epEgD086z2AnrEB2a70zg •⁠ ⁠https://www.instagram.com/p/C6OqvfoNzyG/ •⁠ ⁠https://www.facebook.com/profile.php?id=100095370669614 •⁠ ⁠https://twitter.com/SworldLB •⁠ ⁠https://www.linkedin.com/company/sworld-edu/ Website: -https://sworld-edu.com/

In a 9-6 vote this week, City Council approved an amended plan for re-zoning in Calgary. We catch up with Mayor Jyoti Gondek for her thoughts on the result following the Public Hearings, which were the longest in City Hall's History.  Inflation is impacting how we eat, from dining out to what we put in our cart at the grocery store. Should big food companies do more to create healthier food options at an affordable price and what is the ‘incentive' for these businesses to do so? We tackle the topic with Lana Vanderlee, Canada Research Chair in Healthy Food Policy and Professor of Nutrition at Laval University.   Finally, it's a “cheesy” way to help the local community! Calgary's own “Springbank Cheese” has just opened their 5th location and they're helping feed Calgary kids at the same time! We catch up with Carie Lee and Adrian Watters, Co-owners of Springbank Cheese Company to talk “all things cheese” and, of course, have a ‘nibble' or two.

We're all looking for ways to avoid cognitive decline, whether it's by doing word puzzles or staying fit. So what actually helps keep our brains healthy? Dr. Steven Laureys, neurologist and Canada Excellence Research Chair in neuroplasticity at Laval University, shares what you need to know. For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.

Episode overviewEpisode overviewIn this episode, we are joined by Yvonne Pelling (the Patient and Community Engagement Lead) and Annie LeBlanc (the Nominated Principal Investigator / Scientific Director) of the Strategy for Patient-Oriented Research (SPOR) Passerelle National Training Entity (NTE). Through their engaging discussions, Yvonne and Annie help listeners re-examine what it means to build patient-oriented research capacity among academic researchers, patient partners, and institutions. As a fun bonus, they also explain the meaning of the word “Passerelle” (*hint* it's related to the imagery in the episode's thumbnail image).Meet our guestsYvonne Pelling: is the Patient and Community Engagement Lead at the SPOR Passerelle National Training Entity. Yvonne began her work in patient-oriented research through the SPOR project, Access Open Minds sitting on the Family and Carers Council. This work sparked her interest in capacity building, training, and learning. Yvonne is currently pursuing a Master's Degree in Interdisciplinary Education in Learning Sciences at the University of Calgary. Annie LeBlanc: is the Nominated Principal Investigator / Scientific Director at the SPOR Passerelle National Training Entity. Annie is also a full professor at Laval University in the Faculty of Medicine, and a researcher at Vitam - Laval University's research centre on sustainable health. Annie came to research through her role as a high school teacher and informal caregiver, which inspired her to learn more about patient education and empowerment. Annie obtained a master's degree, a PhD, and then entered into her current roles within the field of Patient-Oriented Research. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit asperusual.substack.com

In the sixth episode of NewGen Mindset's "Capital Market Series," Nic & Dan sit down with Francis Letourneau from NuRAN Wireless. With him, we dive into the evolution of NuRAN and how it has found an opportunity starting in Africa where the majority are heavily under-connected, to be part of the solution. Bridging the connectivity between people in Africa with a cost effective solution putsNuRAN at the forefront of driving the infrastructure revolution for many who have never been able to have a phone or access the internet. Francis Letourneau, Chief Executive Officer, is a seasoned and accomplished Sales and Marketing executive with over 25 years of experience in the telecom industry. Mr.Létourneau is a results-oriented and self-driven professional with 20 years of experience at NuRAN Wireless Inc. Mr. Létourneau was initially promoted to member on the Board of Directors at NuRAN in 2015. This experience has now earned him the title of President and CEO of NuRAN Wireless. Mr. Létourneau has been instrumental in steering NuRAN into a new direction through the implementation NAAS business model, which now defines NuRAN as Mobile Network Operator. As a result of this strategic initiative, NuRAN Wireless has now generated over $550 Millions Dollars in contracts in its initial year as an MNO. Mr. Létourneau holds a bachelor's degree in Business Administration from Laval University, Quebec, Canada and is a Registered Certified Management Accountant (CMA).. NuRAN Wireless Inc., together with its subsidiaries, engages in the research, development, manufacture, marketing, and operation of digital electronic circuits and wireless telecommunication products in Canada, the United States, Europe, Africa, and internationally. The company's products include GSM LiteCell, a GSM base station for rural and roadside coverages, low density villages, remote sites, developing countries/emerging markets, and private networks; OC-2G, a carrier-grade GSM base station; Litecell-xG, a 2G, 3G, and 4G multi-standard base station; Nexus Core Network, a 2G, 3G, and 4G soft core network for small to medium-sized operations, including regional and rural mobile, as well as enterprise private networks; and network as a service Website: https://nuranwireless.com/en/ https://www.newgenmindset.com/ Instagram: @newgenmindsetpod X: @newgen_mindset Disclaimer: None of the information provided in this episode should be considered investment advice and should only be viewed for informational purposes. NewGenMindset is not a broker or a licensed provider of financial services. Any claims made in this episode to any listener should not be regarded as offering personalized legal or investment counseling. Any investments made in any companies should be consulted with a licensed financial professional from here on. #ESG #sustainability #communication #infastructure #wireless #nuran # #cellular #phone #usa #canada #quebec #africa #economy #capitalmarkets #stocks #investing #stockmarket #elon #starlink #satellite #stockstowatch #stockstobuy #2g #3g #4g #internet #solarpower #solarpannel --- Send in a voice message: https://podcasters.spotify.com/pod/show/newgenmindset/message

“The number one thing that I look for when I meet a younger conductor is imagination, someone who comes with ideas but also has a story to tell with the music. Often younger conductors are really worried about technique, the way they look, the way they rehearse, but it starts with imagination. What do you want to communicate? People are so worried about technique that they hide themselves. We want to see the person. Who are you and what do you have to say?”Prof. Jean-Sébastien Vallée is a renowned Canadian-American conductor, scholar, and pedagogue known for his expertise in vocal, choral, and orchestral repertoires. With an illustrious career spanning over several decades, Dr. Vallée has conducted numerous ensembles across North America, Europe, and Asia, and has prepared choruses for some of the world's most prestigious orchestras including the Toronto Symphony, the Montreal Symphony, the National Arts Center Orchestra in Ottawa, and the Chicago Symphony Orchestra.Currently serving as Associate Professor of Music, Director of Choral Studies, and Coordinator of the Ensembles & Conducting Area at the Schulich School of Music of McGill University, and as Artistic Director of the Toronto Mendelssohn Choir, Dr. Vallée is a sought-after conductor and pedagogue. He has previously served as the Director of Choral Studies at California State University, Los Angeles, and was on the choral faculty of the University of Redlands. Dr. Vallée holds degrees from Laval University, Sherbrooke University, the University of California, Santa Cruz, and a doctorate in conducting from the University of Illinois at Urbana-Champaign.Maestro Vallée's passion for contemporary music is evident in his work, as he makes it a priority to premiere and commission works by young composers and program rarely performed repertoire. Dr. Vallée has presented his research at several national and international conferences, including the American Choral Directors Association Conventions, Festival 500 in Newfoundland, the National Collegiate Choral Organization conference, Podium—the national convention of Choral Canada, the Hawaii International Conference on Arts and Humanities, and the World Symposium on Choral Music in Spain (2017), New Zealand (2020), and Portugal (2022).Maestro Vallée's recordings have been broadcast internationally and include Lux (ATMA, 2017), Requiem (ATMA, 2018 – requiems by Fauré and Duruflé), and Distance (ATMA, 2021). His recent engagements include concerts at the Liszt Ferenc Academy of Music in Budapest, a tour with the National Choir of Canada, and concerts with l'Orchestre symphonique de Québec, the Toronto Symphony Orchestra, and the Chicago Symphony Chorus. To get in touch with Jean-Sébastien, you can visit his website jsvallee.com or find him on Facebook (@sebastien.vallee) or Instagram (@jsvallee). Choir Fam wants to hear from you! Check out the Minisode Intro Part 2 episode from May 22, 2023, to hear how to share your story with us.Email choirfampodcast@gmail.com to contact our hosts.Podcast music from Podcast.coPhoto in episode artwork by Trace Hudson

To celebrate Superb Owl weekend (or the big football game for some folks), we decided to throw you an episode about one of our star players, the Snowy Owl!We all love owls! Please take a moment to learn more about safely observing and photographing owls. Join the Great Backyard Bird Count. It takes as little as 15 minutes to make a difference and you can participate from anywhere in the world! The Nocturnal Owl Survey will be looking for helpers from February through April. And the Christmas Bird Count would love your help in December and January.  Andrew Coughlan is a biologist with a wide range of experience working with birds. Born in England, Andrew has lived in Québec since 1996. Before becoming the Director of Quebec for Birds Canada, he worked for 10 years as a research officer at Laval University. Before that, in England, he worked for the Wildfowl and Wetlands Trust and the Zoological Society of London. Andrea Gress (she/her) secretly thinks Piping Plovers are better than all the other birds...studied Renewable Resource Management at the University of Saskatchewan. She pivoted towards birds, after an internship in South Africa. Upon returning, she worked with Piping Plovers in Saskatchewan and now coordinates the Ontario Piping Plover Program for Birds Canada.

On this episode, Dr. Emmanuel Bujold addresses the gross underutilization of acetylsalicylic acid (ASA) in Canada during pregnancy, a treatment highly effective in preventing preterm preeclampsia among those at risk.Dr. Bujold is an OB-GYN in Quebec City and a professor of Obstetrics & Gynecology at Laval University's School of Medicine. He is a co-author of the commentary in CMAJ entitled, “Screening for preeclampsia risk and prophylaxis with acetylsalicylic acid”.Dr. Bujold presents evidence showing ASA's effectiveness in preventing more than 80% of severe preeclampsia cases. He advises that high-risk pregnant women take ASA up to 36 weeks of gestation, with ongoing research potentially adjusting this recommendation.Dr. Bujold describes a simple, relatively inexpensive, and widely available testing protocol that can effectively predict preeclampsia in the first trimester and that starting aspirin before 16 weeks of pregnancy can prevent severe cases.Next, Dr. Modupe Tunde-Byass, an OB-GYN based in Toronto and the inaugural president of the Black Physicians of Canada, emphasizes the disparities in pregnancy outcomes among racialized communities, particularly the higher rates of morbidity and mortality among Black women. She advocates for the implementation of race-based data collection in healthcare to better understand and address these disparities, highlighting the importance of tailored medical approaches to improve outcomes for these communities.This podcast has been sponsored by PrescribeIT. Click here for more information.Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.You can find Blair and Mojola on Twitter @BlairBigham and @DrmojolaomoleTwitter (in English): @CMAJ Twitter (en français): @JAMC FacebookInstagram: @CMAJ.ca The CMAJ Podcast is produced by PodCraft Productions

Today's guest is a first David Beaudoin aka Professor MJ is a real life Moneyball (not the book or movie) sports stats expert who retired at the age of 43 after teaching statistics for 14 years at Laval University because he made over $1 Million cracking the code on how to utilize statistics to beat the house on sports betting in the NFL, MLB, NHL, NBA, WNBA, & NCAA leagues. He considered to be a sports investor instead of a bettor because you are relying on luck.In this conversation, we talk about his career, his retirement age at age 43, his sports investing system and othersKenny The Sports Guy Podcast Twitter: @kenny_sportsInstagram: @kennysportsguy1Tik Tok: @kennysportspodcast David Beaudoin Instagram: @professor__mjTwitter: @DavidBeaudoin79

Today's guest is a first David Beaudoin aka Professor MJ is a real life Moneyball (not the book or movie) sports stats expert who retired at the age of 43 after teaching statistics for 14 years at Laval University because he made over $1 Million cracking the code on how to utilize statistics to beat the house on sports betting in the NFL, MLB, NHL, NBA, WNBA, & NCAA leagues. He considered to be a sports investor instead of a bettor because you are relying on luck.In this conversation, we talk about his career, his retirement age at age 43, his sports investing system and othersKenny The Sports Guy Podcast Twitter: @kenny_sportsInstagram: @kennysportsguy1Tik Tok: @kennysportspodcast David Beaudoin Instagram: @professor__mjTwitter: @DavidBeaudoin79

Welcome to the final of three episodes with Jesse Cook and Dr Jonathan Charest. These episodes break down the excellent review by these two gurus. We break down the lad's recent review and much more in these episodes. Cook, J.D., Charest, J. Sleep and Performance in Professional Athletes. Curr Sleep Medicine Rep 9, 56–81 (2023). https://doi.org/10.1007/s40675-022-00243- Check out Jesse's presentation at the S4P seminar in 2022 Jesse Cook: Circadian Preference, Sleep Inertia, and Running Performance: A retrospective investigation of runner performance from the 2016 London Marathon https://youtu.be/1XRWSynGmRc Jesse is pursuing a doctoral degree in Clinical Psychology at the University of Wisconsin-Madison and currently stands at dissertator status. Previously, he received my Bachelor of Science in Psychology from the University of Arizona (UofA). During his Senior year at the UofA, he began his Sleep research career as an undergraduate research assistant in Dr. Richard Bootzin's, PhD, Sleep Research Laboratory. He has affiliations as a trainee member with the Sleep Research Society, Society of Behavioral Sleep Medicine, and World Sleep Society. He has served as the Sleep Research Society Trainee Member At-large from 2020-2021 and currently serves on the Communications Committee. Also, he has established the Sleep Research Society podcast and currently serves as the host. He enjoys running, biking, cooking, baking, reading, and listening to podcasts/audiobooks in his spare time.   Connect with Jesse LinkedIn https://www.linkedin.com/in/jesse-cook-a89bbb154/ Researchgate https://www.researchgate.net/profile/Jesse-Cook-3 Twitter @sleepandsports Jonathan's previous episode on S4P podcast Season 8, Episode 4 w Dr Jonathan Charest on travel, jet lag, fatigue & performance in the NHL https://www.youtube.com/watch?v=2uKDv3VrFs4&t=390s Dr Jonathan Charest is the Director of Athlete Sleep Services and a Behavioral Sleep Medicine Specialist at the Centre for Sleep & Human performance. He works to develop and optimize sleep for athletes (regional to international level). He focuses on how to optimize sleep, training and travel schedule for athletes, occasional athletes, and student-athletes.  In addition to his bachelor's in psychology (Sherbrooke University), Jonathan completed his PhD in psychology (Laval University). He possesses expertise in behavioural sleep medicine (CBT-I), circadian rhythms disorders, and the specific reality of the athletic population. Jonathan has been an invited public speaker for sleep at International Conferences.  As an ex-athlete, Jonathan believes in the importance of sleep, recovery and regeneration in the performance environment and, alongside Dr Samuels and the entire team at CSHP, brings a strong commitment to athletes, coaches, and teams to deliver education, screening tools, and research-based strategies to establish healthy sleep hygiene for athletes throughout their career, and for a lifetime. Connect with Jonathan LinkedIn https://www.linkedin.com/in/dr-jonath... Twitter https://twitter.com/jocharest1?lang=en Research Gate https://www.researchgate.net/profile/... Contact me at iandunican@sleep4performance.com.au or www.sleep4performance.com.au  and check out the YouTube channel. Check out our sponsor, LMNT. Click on the link to order and get a free LMNT Sample Pack when you order through the custom link below. Key details:   The LMNT Sample Pack includes 1 packet of every flavour. This is the perfect offer for anyone interested in trying all our flavours or wanting to introduce a friend to LMNT. This offer is exclusively available through VIP LMNT Partners – you won't find this offer publicly available. This offer is available for new and returning customers. They offer refunds on all orders with no questions – you don't even have to send it back! http://drinklmnt.com/sleep4performance

Jean-Pierre Corbeil, Adjunct professor in department Of Sociology at Laval University and former head of language statistics program at Statistics Canada

Lauren Coyle, Editor, Immuno-Oncology Insights, speaks with Raoul Santiago, Clinical Investigator and Associate Professor of Pediatric Hematology and Oncology, University Hospital Center, Laval University, to discuss the role of multiomics in the I-O setting and how these tools can be leveraged to improve pediatric cancer care.

Host: John Buse, MD, PhD Guest: Jean-Philippe Drouin-Chartier, DtP, PhD What's the relationship between ultra-processed food consumption and the risk of developing type 2 diabetes? Find out with Dr. John Buse as he speaks with Dr. Jean-Philippe Drouin-Chartier about his research that sought to answer this exact question. Dr. Drouin-Chartier is an Assistant Professor at the Faculté de Pharmacie at Laval University and a researcher in the Nutrition, Health, and Society Center of the Institute on Nutrition and Functional Foods in Quebec, Canada.

Frencesco Cavatorta, Professor of Political Science at Laval University in Quebec and co-author of the textbook Politics and Governance in the Middle East

Within the dairy industry, the synergy of genomics, reproduction, and technological advances drives transformative change, pivotal for enhancing milk production, animal health, and profitability. Genomics facilitates precise breeding and trait selection, while reproductive technologies like in-vitro fertilization (IVF) revolutionize cattle propagation. In this episode, Dr. Marc André Sirard, a Professor at Laval University, discusses his valuable contributions to the field. Dr. Sirard shares his pioneering work about IVF for cattle, the role of epigenetics in dairy farming, and innovative insights on fertility and genetics. "The environment, especially nutrition, can influence the epigenetic programming of cattle, affecting their health and productivity."What you'll learn:(00:00) Highlight(02:08) Introduction(05:20) Dr. Sirard's contributions to IVF(09:26) IVF for accelerating genetic gain(13:22) How environment influences epigenetics(22:58) Impact of diet on genetic modulation(29:47) Genetic analysis and fertility issues(36:27) The final questionsMeet the guest: Dr. Marc André Sirard Experience:Current: Professor at the Laval UniversityBackground:Ph.D. in Reproduction (Laval University)DMV in Veterinary Medicine (Montreal University)Connect with the guest!The Dairy Podcast Show is trusted and supported by innovative companies like:* Adisseo- Diamond V- dsm-firmenich- Evonik- ICC- Phibro- Protekta- smaXtec- AB Vista- Berg + Schmidt

Welcome to the secont of three episodes with Jesse Cook and Dr Jonathan Charest. These episodes break down the excellent review by these two gurus. We break down the lad's recent review and much more in these episodes. Cook, J.D., Charest, J. Sleep and Performance in Professional Athletes. Curr Sleep Medicine Rep 9, 56–81 (2023). https://doi.org/10.1007/s40675-022-00243- Check out Jesse's presentation at the S4P seminar in 2022 Jesse Cook: Circadian Preference, Sleep Inertia, and Running Performance: A retrospective investigation of runner performance from the 2016 London Marathon https://youtu.be/1XRWSynGmRc Jesse is pursuing a doctoral degree in Clinical Psychology at the University of Wisconsin-Madison and currently stands at dissertator status. Previously, he received my Bachelor of Science in Psychology from the University of Arizona (UofA). During his Senior year at the UofA, he began his Sleep research career as an undergraduate research assistant in Dr. Richard Bootzin's, PhD, Sleep Research Laboratory. He has affiliations as a trainee member with the Sleep Research Society, Society of Behavioral Sleep Medicine, and World Sleep Society. He has served as the Sleep Research Society Trainee Member At-large from 2020-2021 and currently serves on the Communications Committee. Also, he has established the Sleep Research Society podcast and currently serves as the host. In his spare time, he enjoys run, biking, cooking, baking, reading, and listening to podcasts/audiobooks.   Connect with Jesse LinkedIn https://www.linkedin.com/in/jesse-cook-a89bbb154/ Researchgate https://www.researchgate.net/profile/Jesse-Cook-3 Twitter @sleepandsports Jonathan's previous episode on S4P podcast Season 8, Episode 4 w Dr Jonathan Charest on travel, jet lag, fatigue & performance in the NHL https://www.youtube.com/watch?v=2uKDv3VrFs4&t=390s Dr Jonathan Charest is the Director of Athlete Sleep Services and a Behavioral Sleep Medicine Specialist at the Centre for Sleep & Human performance. He works to develop and optimize sleep for athletes (regional to international level). He focuses on how to optimize sleep, training and travel schedule for athletes, occasional athletes, and student-athletes.  In addition to his bachelor's in psychology (Sherbrooke University), Jonathan completed his PhD in psychology (Laval University). He possesses expertise in behavioural sleep medicine (CBT-I), circadian rhythms disorders, as well as the specific reality of the athletic population. Jonathan has been an invited public speaker for sleep at International Conferences.  As an ex-athlete, Jonathan believes in the importance of sleep, recovery and regeneration in the performance environment and, alongside Dr Samuels and the entire team at CSHP, brings a strong commitment to athletes, coaches, and teams to deliver education, screening tools, and research-based strategies to establish healthy sleep hygiene for athletes throughout their career, and for a lifetime. Connect with Jonathan LinkedIn https://www.linkedin.com/in/dr-jonath... Twitter https://twitter.com/jocharest1?lang=en Research Gate https://www.researchgate.net/profile/...   Contact me at iandunican@sleep4performance.com.au or www.sleep4performance.com.au  and check out the YouTube channel. Check out our sponsor, LMNT. Click on the link to order and get a free LMNT Sample Pack when you order through the custom link below. Key details:   The LMNT Sample Pack includes 1 packet of every flavour. This is the perfect offer for anyone interested in trying all our flavours or wanting to introduce a friend to LMNT. This offer is exclusively available through VIP LMNT Partners – you won't find this offer publicly available. This offer is available for new and returning customers. They offer refunds on all orders with no questions – you don't even have to send it back! http://drinklmnt.com/sleep4performance

Foresters love a challenge! And one such challenge in eastern Northern America has always been northern white-cedar (Thuja occidentalis). A both ecologically and commercially valuable tree species that can be slow-growing, tricky to regenerate, and highly susceptible to deer browse. Join us on this episode of SilviCast as we introduce you to the Cedar Club, a passionate group of forest practitioners and researchers who have been tackling the cedar management question for the pat 23 years. Explore the challenges and opportunities to sustainable management of northern white-cedar.Featured "Cedar Club" Guests: ​Dr. Laura Kenefic, Research Forester and Team Leader, USFS, Northern Research Station; Jean-Claude Ruel, Emeritus Silviculture Professor, Laval University; Charles Tardif, Vice President Manufacturing, Maibec; Dr. Olivier Villemaire-Côté​, Institut des Sciences de la Forêt Tempérée (ISFORT-UQO); and Victoria Hunter, Graduate Student, Michigan Technological University

Welcome to the first three episodes with Jesse Cook and Dr Jonathan Charest. These episodes break down the excellent review by these two gurus. We break down the lad's recent review and much more in these episodes. Cook, J.D., Charest, J. Sleep and Performance in Professional Athletes. Curr Sleep Medicine Rep 9, 56–81 (2023). https://doi.org/10.1007/s40675-022-00243- Check out Jesse's presentation at the S4P seminar in 2022 Jesse Cook: Circadian Preference, Sleep Inertia, and Running Performance: A retrospective investigation of runner performance from the 2016 London Marathon https://youtu.be/1XRWSynGmRc Jesse is pursuing a doctoral degree in Clinical Psychology at the University of Wisconsin-Madison and currently stands at dissertator status. Previously, he received my Bachelor of Science in Psychology from the University of Arizona (UofA). During his Senior year at the UofA, he began his Sleep research career as an undergraduate research assistant in Dr. Richard Bootzin's, PhD, Sleep Research Laboratory. He has affiliations as a trainee member with the Sleep Research Society, Society of Behavioral Sleep Medicine, and World Sleep Society. He has served as the Sleep Research Society Trainee Member At-large from 2020-2021 and currently serves on the Communications Committee. Also, he has established the Sleep Research Society podcast and currently serves as the host. In his spare time, he enjoys run, biking, cooking, baking, reading, and listening to podcasts/audiobooks.   Connect with Jesse LinkedIn https://www.linkedin.com/in/jesse-cook-a89bbb154/ Researchgate https://www.researchgate.net/profile/Jesse-Cook-3 Twitter @sleepandsports Jonathan's previous episode on S4P podcast Season 8, Episode 4 w Dr Jonathan Charest on travel, jet lag, fatigue & performance in the NHL https://www.youtube.com/watch?v=2uKDv3VrFs4&t=390s Dr Jonathan Charest is the Director of Athlete Sleep Services and a Behavioral Sleep Medicine Specialist at the Centre for Sleep & Human performance. He works to develop and optimize sleep for athletes (regional to international level). He focuses on how to optimize sleep, training and travel schedule for athletes, occasional athletes, and student-athletes.  In addition to his bachelor's in psychology (Sherbrooke University), Jonathan completed his PhD in psychology (Laval University). He possesses expertise in behavioural sleep medicine (CBT-I), circadian rhythms disorders, as well as the specific reality of the athletic population. Jonathan has been an invited public speaker for sleep at International Conferences.  As an ex-athlete, Jonathan believes in the importance of sleep, recovery and regeneration in the performance environment and, alongside Dr Samuels and the entire team at CSHP, brings a strong commitment to athletes, coaches, and teams to deliver education, screening tools, and research-based strategies to establish healthy sleep hygiene for athletes throughout their career, and for a lifetime. Connect with Jonathan LinkedIn https://www.linkedin.com/in/dr-jonath... Twitter https://twitter.com/jocharest1?lang=en Research Gate https://www.researchgate.net/profile/...   Contact me at iandunican@sleep4performance.com.au or www.sleep4performance.com.au  and check out the YouTube channel. Check out our sponsor, LMNT. Click on the link to order and get a free LMNT Sample Pack when you order through the custom link below. Key details:   The LMNT Sample Pack includes 1 packet of every flavour. This is the perfect offer for anyone interested in trying all our flavours or wanting to introduce a friend to LMNT. This offer is exclusively available through VIP LMNT Partners – you won't find this offer publicly available. This offer is available for new and returning customers. They offer refunds on all orders with no questions – you don't even have to send it back! http://drinklmnt.com/sleep4performance

Getting your product to market has many steps, and a crucial one is developing a compliant nutrition facts label. Food labeling (https://bakerpedia.com/food-safety/food-labeling/) needs to be easily understood by consumers and must comply with federal regulations. Proper food labeling is vital to a product's success, as products that do not comply or are in violation of the regulations may be subject to recall. In this episode of BAKED in Science, host Mark Floerke is joined by three nutrition, food regulation, and allergen labeling experts to explore the nuances of the nutrition facts label. Lauren Swann is a Registered Dietitian with a Master of Science in Nutrition Communications and a Licensed Dietitian Nutritionist in the state of Pennsylvania. With over 40 years of experience, she has worked for companies such as Concept Nutrition, Inc., (https://foodfactswork.com)Kraft Foods Group, and Vlasic Foods & The Pinnacle Food Corporation. Kamran Khan is a food regulation compliance professional with a Master of Science in Chemistry. After 10 years of experience in analytic testing in a food laboratory, he got his start in food regulation when India rolled out stricter food safety and standard regulations. Sam Godefroy is a professor of Food Risk Analysis and Regulatory Policies in the Department of Food Science at Laval University. He is also a founding member of the Global Food Regulatory Science Society. (https://gforss.org) Focusing on food labeling As these three food experts discuss the current landscape of labeling and health claims, some topics covered include: - Considerations for nutrition facts labeling - Nutrient content claims as defined by the FDA - Health claims and regulations for food exports - Regulations surrounding allergen labeling - Allergen management practices

In this episode, I talk with my friend Jonathan Charest from Calgary, Canada. Jonathan is a native of Quebec, Canada and is a crazy Ice Hockey fan. In this episode, we discuss Jonathan's latest paper. Associations between time zone changes travel distance and performance: A retrospective analysis of 2013–2020 National Hockey League Data by Charest, Jonathan et al. published in the Journal of Science and Medicine in Sport, Volume 25, Issue 12, 1008 – 1016 https://www.jsams.org/article/S1440-2440(22)00439-X/fulltext Jonathan Charest is the Director of Athlete Sleep Services and a Behavioral Sleep Medicine Specialist at the Centre for Sleep & Human performance. He works to develop and optimize sleep for athletes (regional to international level). He focuses on how to optimize sleep, training and travel schedule for athletes, occasional athletes, and student-athletes.  In addition to his bachelor's in psychology (Sherbrooke University), Jonathan is currently completing his PhD in psychology (Laval University). He possesses expertise in behavioural sleep medicine (CBT-I), circadian rhythms disorders, as well as the specific reality of the athletic population. Jonathan has been an invited public speaker for sleep at International Conferences.  As an ex-athlete, Jonathan believes in the importance of sleep, recovery and regeneration in the performance environment and, alongside Dr Samuels and the entire team at CSHP, brings a strong commitment to athletes, coaches, and teams to deliver education, screening tools, and research-based strategies to establish healthy sleep hygiene for athletes throughout their career, and for a lifetime.   Connect with Jonathan LinkedIn https://www.linkedin.com/in/dr-jonathan-charest-98647733/ Twitter https://twitter.com/jocharest1?lang=en Research Gate https://www.researchgate.net/profile/Jonathan-Charest-4   Contact me at iandunican@sleep4performance.com.au or www.sleep4performance.com.au  and check out the YouTube channel. Check out our sponsor, LMNT. Click on the link to order and get a free LMNT Sample Pack when you order through the custom link below. Key details:   The LMNT Sample Pack includes 1 packet of every flavour. This is the perfect offer for anyone interested in trying all our flavours or wanting to introduce a friend to LMNT. This offer is exclusively available through VIP LMNT Partners – you won't find this offer publicly available. This offer is available for new and returning customers. They offer refunds on all orders with no questions – you don't even have to send it back! http://drinklmnt.com/sleep4performance  

Seg 1 - With inflation projected to be in decline, the Bank of Canada is set to pause on interest rate hikes. Guest: Stephen Gordon, Professor of Economics at Laval University. Seg 2 - Is the VPD out of control and too political? Guest: Ian Mulgrew, Vancouver Sun Columnist Seg 3 - Some mayors are pushing for the end to vaccine mandates in the healthcare industry in order to get more nurses back to work. Guest: Shirley Bond, BC Liberal MLA and Health critic Seg 4 - Intense cold coming to Metro Vancouver this weekend could last weeks Guest: Jonathan Bau, Environment Canada Meteorologist Seg 5 - The government is protecting a rare ecosystem near Revelstoke BC! Guest: George Heyman, BC Minister of Environment and Climate Change Strategy Learn more about your ad choices. Visit megaphone.fm/adchoices

With inflation projected to be in decline, the Bank of Canada is set to pause on interest rate hikes. Guest: Stephen Gordon, Professor of Economics at Laval University. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Lung Cancer Considered, host Dr. Stephen Liu, Director of Thoracic Oncology at Georgetown University, leads a discussion about the management of stage III NSCLC. Joining him are pulmonologist Dr. Martin Reck, Head of the Department of Thoracic Oncology and the Head of the Clinical Trials Department at the Lung Clinic Grosshansdorf and thoracic surgeon Dr. Paula Antonia Ugalde Figueroa, an Associate Surgeon in the Division of Thoracic Surgery at Brigham and Women's Hospital in Boston, MA. Dr. Reck has led many of the oncology trials that have defined the standard of care for lung cancer including KEYNOTE-024 and more recent efforts in stage III NSCLC like KEYNOTE-799. Dr. Ugalde has been a pioneer in minimally invasive surgery from her time as director of Thoracic Oncology research at Laval University in Quebec to her current position at the Dana Farber Cancer Institute. She is currently a member of the Board of Directors of IASLC.

Host Jonathan Sackier is joined by Steven Laureys, acclaimed neurologist, Founding Director of the GIGA Consciousness Research Unit, Liège University Hospital, Belgium, and Associate Professor at the CERVO Research Centre, Laval University, Québec, Canada. They discuss human consciousness, the ability of the brain to adapt in different situations, and the power of meditation. Steven Laureys' Website: https://www.drstevenlaureys.org/  The No-Nonsense Meditation Book: https://www.blinkist.com/en/books/the-no-nonsense-meditation-book-en Interview with Steven Laureys and Matthieu Ricard: https://www.youtube.com/watch?v=2ALsGqR1PHA Ted Talk - Consciousness in Babies: https://www.ted.com/talks/steven_laureys_consciousness_in_babies Ted Talk - Brain Concussion: Shake It and You Break It: https://www.youtube.com/watch?v=5nBqLwg2Eug&ab_channel=TEDxTalks Ted Talk - From Brain to Consciousness: https://www.youtube.com/watch?v=6Qqc_wJS6-Q&ab_channel=TEDxTalks

In this episode of Run with Fitpage, we had one of the top researchers in the world - Dr. Claude Bouchard. Dr. Bouchard is a Professor and the John W. Barton, Sr. Endowed Chair in Genetics and Nutrition at Louisiana State University's Pennington Biomedical Research Center (PBRC), where he is also the Director of the Human Genomics Laboratory. Vikas and Dr. Bouchard talk all about obesity, and the role of genetics in this episode.Dr. Bouchard is known for his research on the role of genetics in obesity and in the process of adaptation to regular physical activity. He was president of the Obesity Society in 1991–92. Bouchard graduated from Laval University with a B.P.Ed degree in 1962. He received his M.Sc. in exercise physiology from the University of Oregon the following year before doing postgraduate work at the University of Cologne and the German Sport University Cologne in Germany for two years (1963–65). In 1977, he received his Ph.D. from the University of Texas at Austin, after which he completed his postdoc at the University of Montreal in the same year. In 1999, after teaching kinesiology at Laval University for over thirty years, he joined the faculty of the Pennington Biomedical Research Center, where he was the Executive Director and George A. Bray Chair in Nutrition until 2010.Dr. Bouchard has been a fellow of the Royal Academy of Medicine of Belgium since 1996. He became an Officer of the Order of Leopold II of Belgium in 1994, a member of the Order of Canada in 2001, and a Chevalier in the Ordre National du Quebec in 2005. In 2002, he received the Honor Award from the American College of Sports Medicine. He is a fellow of the American College of Sports Medicine, the American Society for Nutrition, the Obesity Society, the American Heart Association, and the American Association for the Advancement of Science. In 2016, the Louisiana State University (LSU) Board of Supervisors voted unanimously to award him a Boyd Professorship, the most prestigious title that can be awarded to professors at LSU.Vikas hosts this weekly podcast and enjoys nerding over-exercise physiology, nutrition, and endurance sport in general.  He aims to get people to get out and 'move'.  When he is not working, he is found running, almost always.  He can be found on nearly all social media channels but Instagram is preferred:)Reach out to Vikas:Instagram: @vikas_singhhLinkedIn: Vikas SinghTwitter: @vikashsingh1010

New research shows that news coverage of word events is not captivating audiences the way it once did. But why do people seem to be increasingly tuning out the news? For insights we welcome: Adam Mastroianni, Post-Doctoral Fellow at the Columbia School of Business; investigative journalist Amanda Ripley; and Colette Brin, director of the Center for Media Studies at Laval University.See omnystudio.com/listener for privacy information.

Hello everyone.  Welcome to another exciting episode of VR in Education.  In today's episode, we are talking with Hosni Zaouali, the CEO of Tech Adaptika.  Hosni knew, even at a young age, that education would be the catalyst to propel him forward and empower him to help others.  He has an impressive formal education background.  Hosni has a B.A ENG in Nuclear Engineering from the Sorbonne in Paris and a MBA in International Development from Laval University.  He was founder of Voilà Learning, a company that offered online French education, mostly for people in Africa, and taught an Online Executive Program for Stanford University.  What an impressive background.  You can reach him on LinkedIn at https://www.linkedin.com/in/hosninio/ 

Ch1: Economists are predicting the Bank of Canada will hike its key interest rate by three-quarters of a percentage point on Wednesday as inflation rages on globally. Guest: Stephen Gordon, Professor of Economics at Laval University. Ch2: Amid what many are calling a health-care crisis, those on the front lines want Canadian premiers, who will gather for their first in-person meeting since 2019, to come up with a concrete action plan. Guest: Dr. Katherine Smart, President of the Canadian Medical Association. Ch3: The Rogers service outage last week is being called a wakeup call for the Federal government's digital policies. Guest: Michael Geist, Canada Research Chair in Internet and E-Commerce Law, University of Ottawa Ch4: As airlines continue to juggle a chaotic summer of travel, some airlines have already announced that they will decrease their flight service. How will this impact tourism? Guest: Walt Judas, CEO of BC Tourism Association. Ch5: A barge from Ontario was stopped last month from potentially infesting B.C. waters with invasive mussels. Guest: Gail Wallin, Executive Director of Invasive Species of BC.

For more details, visit the #DrGPCR Podcast Episode #71 page https://www.drgpcr.com/episode-71-with-dr-jean-martin-beaulieu ------------------------------------------- About Dr. Jean Martin Beaulieu Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University. Dr. Beaulieu's research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents. Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs. In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology. Dr. Jean Martin Beaulieu on the web University of Toronto Google Scholar LinkedIn ResearchGate ------------------------------------------- We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together. Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space! For more details, visit our website http://www.DrGPCR.com/Ecosystem/.

On Episode 15 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the April 2022 issue of Stroke: “Kawasaki Disease May Increase the Risk of Subsequent Cerebrovascular Disease” and “Effect of Moderate and Severe Persistent Hyperglycemia on Outcomes in Patients With Intracerebral Hemorrhage.” She also interviews Dr. François Gros-Louis about his article “Moyamoya Disease Susceptibility Gene RNF213 Regulates Endothelial Barrier Function.” Dr. Negar Asdaghi:                        1) How would you counsel the parent of a child who has just recovered from Kawasaki disease on their child's future risk of having a stroke? 2) Should we or should we not treat stress hyperglycemia in the setting of acute intracerebral hemorrhage? 3) What is the CRISPR-Cas9 gene editing technology? And why, if you haven't heard of it already, you most definitely should be listening to this podcast? We're back here with the April issue of the Stroke Alert Podcast, and this is the latest in Stroke. Stay with us. Dr. Negar Asdaghi:                        Welcome back to another extremely informative Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine, and your host for the monthly Stroke Alert Podcast. The April 2022 issue of Stroke contains a range of really exciting papers and topics. In the paper titled "Vascular Response to Spreading Depolarization Predicts Stroke Outcome," we have a really interesting in vivo mouse model of ischemic stroke, looking at the spreading patterns of cortical depolarization and the subsequent vascular response to this by way of hyperemia. The researchers from Zurich University, led by Dr. Binder and colleagues, walk us through how the patterns of hyperemia can actually predict the severity of subsequent ischemic injury. Dr. Negar Asdaghi:                        In a separate paper in this issue of the journal, we're reminded of how the classic NIH Stroke Scale can underestimate the severity of neurological symptoms and outcomes in patients with posterior circulation infarcts. In the paper led by Dr. Alemseged and colleagues, the investigators from the Royal Melbourne Hospital in Australia evaluate the prognostic accuracy of the Posterior NIH Stroke Scale, which is the modified version of the classic NIH Stroke Scale, in predicting the outcomes of patients with posterior circulation infarcts. Dr. Negar Asdaghi:                        I encourage you to review these papers in addition to listening to our podcast today. Later in the podcast, I have the great pleasure of interviewing Dr. François Gros-Louis from Laval University in Quebec to discuss the latest in gene editing technology and how this technology has helped his team unravel the biological function of RNF213 susceptibility gene in Moyamoya disease. But first with these two articles. Dr. Negar Asdaghi:                        Kawasaki disease, which was first described in 1976, is an acute febrile illness predominantly affecting children younger than five years of age. In addition to fever, other clinical signs of the disease include rash, bilateral conjunctival injection, cervical lymphadenopathy, swelling of the hands and feet, and irritation and inflammation of the mouth, lips, and throat. Now, for those of us like me who are adult neurologists, here is a quick review of the pathophysiology of Kawasaki disease. Dr. Negar Asdaghi:                        This is a medium vessel vasculopathy, most significantly affecting the coronary arteries, a vasculopathy that is characterized by three linked pathological processes, necrotizing arteritis, subacute to chronic vasculitis, and luminal myofibroblastic proliferation. So, simply put, these processes can lead to stenotic lesions in various vascular beds, which are affected by this disease. Dr. Negar Asdaghi:                        And as we mentioned earlier, the most recognized vascular blood vessels affected by Kawasaki disease are the coronary arteries, which can lead to myocardial ischemia, infarction, and sudden death in these cases. However, involvement of other vascular beds, including cerebral vessels, are also increasingly reported as part of Kawasaki disease. Dr. Negar Asdaghi:                        So, in the current issue of the journal, Dr. Chien-Heng Lin from the Division of Pediatric Pulmonology at China Medical University Children's Hospital in Taiwan and colleagues studied the subsequent risk of cerebrovascular events in patients with Kawasaki disease. Using the National Health Insurance Research Database of Taiwan, they collected data on 8467 children with Kawasaki disease from 2000 to 2012. And for each child with Kawasaki, data was also collected on four randomly selected non-Kawasaki disease children who were matched with the Kawasaki cohort for sex, urbanization level of residence, and parental occupation. Dr. Negar Asdaghi:                        So, that gave them a sample size of over 33,000 children for their non-Kawasaki cohort. And then they compared the risk of subsequent stroke in children between the two cohorts. The study period for any given patient would end when the said patient was either diagnosed with a cerebrovascular disease or withdrew from the research database. Dr. Negar Asdaghi:                        So, in terms of their demographics, 61% of patients in the Kawasaki group were boys; 88% of the Kawasaki cohort were younger than five years of age. So, here are the findings. Number one, the incident rate of subsequent cerebrovascular disease was 14.7 per hundred thousand person years in the Kawasaki cohort versus only 4.6 per hundred thousand person years in the non-Kawasaki cohort. That's greater than a threefold higher incidence rate of cerebrovascular disorders for children who had Kawasaki disease before. Dr. Negar Asdaghi:                        This finding was independent of other potential confounders, which they adjusted for in their multivariate analysis. Now, the length of follow up was a median of 9.8 years for the entire cohort. And on the issue of time, they found two important associations. The first finding was that when the follow-up time was stratified by five-year periods, Kawasaki disease cohort patients showed a significantly higher risk of developing a stroke within the first five years after being diagnosed. Dr. Negar Asdaghi:                        And the second important association was that when they looked at the age at the time of diagnosis of Kawasaki, children who were younger than five years at the time of diagnosis were at a significantly higher risk of having a future stroke as compared to those who were older than five at the time of diagnosis. Dr. Negar Asdaghi:                        So, simply put, the risk of subsequent stroke was higher in children who acquired the disease at a younger age, and that risk was higher in the first few years after the diagnosis of Kawasaki disease. The authors discuss a number of putative mechanisms to link Kawasaki with stroke. The most important being a cardiac source of embolism that we already alluded to, but other etiologies, including medium vessel cerebral vasculitis, or hypercoagulability in the setting of increased systemic inflammation, and even Kawasaki disease-associated aneurysmal rupture to cause hemorrhagic forms of stroke, are discussed in the paper and should be considered in the correct setting in children with a prior history of this disease. Dr. Negar Asdaghi:                        So, what we learned from this large population-based pediatric study is that Kawasaki disease does indeed increase the risk of subsequent cerebrovascular disorders, and its influence is stronger in children who are diagnosed with this condition under the age of five, and the time period during which the risk of stroke is the highest is within the first five years after the diagnosis. Dr. Negar Asdaghi:                        In the setting of spontaneous intracerebral hemorrhage, or ICH, much research has focused on the association between hypertension and blood pressure-lowering therapies and hematoma expansion and functional outcomes, but a lot less attention relatively has been given to the impact of hyperglycemia and ICH-related outcomes. Dr. Negar Asdaghi:                        The current guidelines state that serum glucose should be monitored and both hypo- and hyperglycemia should be avoided in the setting of ICH. The older studies have given us inconsistent results as to whether or not hyperglycemia can increase the risk of ICH-related mortality. More recent studies have suggested that perhaps persistent hyperglycemia is indeed a predictor of poor neurological outcomes in ICH, but these results come from smaller single-center studies, which require further confirmation. And this confirmation is exactly what Dr. Adnan Qureshi from Zeenat Qureshi Stroke Institute and the Department of Neurology at University of Missouri and colleagues aim to give us in their study titled "Effect of Moderate and Severe Persistent Hyperglycemia on Outcomes in Patients With Intracerebral Hemorrhage." Dr. Negar Asdaghi:                        So, they use data from the ATACH-2 study, and a quick reminder that ATACH-2 was a multicenter randomized control trial of a thousand patients with acute spontaneous intracerebral hemorrhage enrolled within four and a half hours from symptom onset, and patients were randomized to either the intensive blood pressure control treatment arm to maintain their systolic blood pressure goal of 110 to 139 millimeter of mercury versus standard treatment arm, which was keeping their systolic blood pressure above 140, between 140 to 179 millimeter of mercury, in the first 24 hours after randomization. Dr. Negar Asdaghi:                        You will recall that enrollment of ATACH-2 was stopped early because of futility after pre-specified interim analysis. The main results of the trial was published in 2016 in New England Journal of Medicine, and the primary results did not show a lower rate of death or disability in patients assigned to the intensive treatment group. Dr. Negar Asdaghi:                        So, in the current paper, in this current issue of the journal, the authors looked at the glycemic status of the patients enrolled in the trial. As part of the trial, patients had a complete chemistry panel at baseline, 24, 48, and 72 hours from onset. So, they used the glucose measurement from this panel and defined moderate hyperglycemia as serum glucose level of over 140 and under 180 and severe hyperglycemia as serum glucose levels of equal or greater than 180. Dr. Negar Asdaghi:                        Now, persistent hyperglycemia was if two consecutive serum glucose levels were in the moderate or severe categories. And, very simply, they looked at the effects of hyperglycemia on ICH outcomes. And importantly, they evaluated whether hyperglycemia modified the effects of intensive blood pressure reduction on outcomes of ICH. So, of the thousand participants in ATACH-2, 11% had persistent moderate hyperglycemia, and 17% had severe persistent hyperglycemia. Those in the hyperglycemic group were more likely to be diabetic, not surprisingly, more likely to have a history of hypertension and dyslipidemia as compared to the normal glycemic patients. Dr. Negar Asdaghi:                        And here are the results. Number one, serious adverse events were higher in the hyperglycemic groups, whether we're talking about the moderate or the severe hyperglycemic groups. This is despite the fact that the rate of hematoma expansion and perihematomal edema was not different based on the hyperglycemic status. However, the hyperglycemic patients were more likely to have serious adverse events, which were operationally defined as complications that were not expected to have occurred from the study intervention, in this case, the intensive hypertensive therapy, and resulted in either death or prolonged hospitalization or persistent or significant disabilities. Now, serious renal adverse events, which are, of course, expected as a complication for aggressive blood pressure therapy, were also significantly higher in the hyperglycemic category. Dr. Negar Asdaghi:                        Now, their next important finding was that overall, both moderate and severe hyperglycemia was associated with higher odds of 90 days disability or death post-ICH adjusting for typical variables that could predict these outcomes, such as GCS score, hematoma volume, presence or absence of intraventricular hemorrhage, amongst other factors that they accounted for. Dr. Negar Asdaghi:                        Now, number three, this is perhaps the most important finding of the study. Among patients without a preexisting history of diabetes, both moderate and severe hyperglycemia increased the risk of death and disability at 90 days after adjusting for all the potential confounders, but hyperglycemia was not associated with these poor outcomes in those with a prior history of diabetes. I'm going to pause here to let this information sink in. Let's go over them again, stress hyperglycemia in non-diabetics was associated with poor ICH outcomes, but high sugars in diabetics did not predict the same poor outcomes. And finally, they looked at the possible interactions between the glycemic status and the ATACH-2 intervention, which as we alluded to earlier, which was intensive versus standard blood pressure therapy, and it turns out that the intensive systolic blood pressure reduction was indeed associated with a lower rate of hematoma expansion only in patients with normal glycemia, but not in those with moderate or severe hyperglycemia. Dr. Negar Asdaghi:                        So, this is again food for thought. Simply put, if the sugars are not well controlled, it appears that intensive blood pressure control would not lower the rate of hematoma expansion. Blood pressure lowering works when the sugar levels are controlled. So, overall, here are the two simple messages of this study. Number one, hyperglycemia in the acute setting of intracerebral hemorrhage is associated with poor outcomes or death only in those with stress hyperglycemia, meaning in those who have high sugar levels, but are not diabetic. Dr. Negar Asdaghi:                        Number two, there seems to be an important interaction between the acute glycemic status of the patients and how intensive blood pressure control can prevent hematoma expansion, in that intensive BP control is only effective in prevention of hematoma expansion if the sugar levels are normal. So, a lot of thought-provoking and hypothesis-generating findings, and definitely more to come on this topic. Dr. Negar Asdaghi:                        Moyamoya disease, or MMD, is an idiopathic disorder characterized by progressive stenosis of the supraclinoid internal carotid artery and its main branches in subsequent formation of a network of abnormal lenticulostriate collaterals. First described in Japan, the term "Moyamoya" is a Japanese expression for the puff of smoke and describes the characteristic appearance of the tangled and abnormal collateral vessels that are seen in angiography in various stages of the Moyamoya disease. Dr. Negar Asdaghi:                        Epidemiological studies have revealed several risk factors associated with Moyamoya disease, including Asian ethnicity, female gender, and a family history of the disorder. Given that 15% of MMD patients have a family history of this disease, it's not surprising that genetic factors are suspected to underlie its pathogenesis. Now, a polymorphism in the ring finger protein 213, or RNF213, gene on chromosome 17 has been identified as the strongest genetic susceptibility factor for Moyamoya disease specifically in the East Asian population. Dr. Negar Asdaghi:                        But despite the many advances in understanding the pathophysiology of MMD, as well as advances in animal models and genetic studies, to date, none of the animal models of RNF213 have quite replicated the vascular abnormalities that are typically seen in human Moyamoya disease. Dr. Negar Asdaghi:                        The scientists feel that this is related to how little is known about the exact biological function of RNF213 gene and the protein it encodes. So, in the current issue of the journal, in the study titled "Moyamoya Disease Susceptibility Gene RNF213 Regulates Endothelial Barrier Function," Dr. François Gros-Louis from CHU de Québec Research Center at Laval University in Québec and colleagues aim to study the biological functions of RNF213 using a novel genome editing technology by the name of CRISPR-Cas9 technology. Dr. Negar Asdaghi:                        Joining me now is Dr. Gros-Louis himself to discuss the findings of this paper. Dr. Gros-Louis is a Professor of Neurosciences at the Department of Surgery at Laval University. He holds the Canada Research Chair in Brain Disease Modeling and is the Director of the Induced Pluripotent Stem Cell Platform research in Québec. Dr. Negar Asdaghi:                        Good morning, François. Welcome to our podcast. And thank you so much for joining us. Dr. François Gros-Louis:               My pleasure. Dr. Negar Asdaghi:                        François, you have to promise to hold my clinician's hand through this interview as obviously these are some foreign subjects for us, but very excited to learn from your study and learn from you on the association between RNF213 and the pathophysiology of what happens in Moyamoya disease. Now, before we talk about your paper, can you please talk to us about some basic concepts? What is the RNF213 protein? Dr. François Gros-Louis:               Yes. The RNF213 gene is thought to be involved in mediating protein, protein interactions. The protein also contains a domain which is associated with an ATPase activity. This gene is a susceptibility gene for Moyamoya disease, as you mentioned in the introduction, vascular disorder of intracranial arteries. It's encoded in ubiquitously expressed protein. The protein is found to be expressed throughout the cytocell with the partial association in the intracellular membrane and cytoskeleton. Its expression varies according to the tested tissue type or location or cellular types. Dr. François Gros-Louis:               Although the function of RNF213 protein is unknown, studies suggest that it plays a role in the proper development of blood vessels, cell proliferation, and inflammation. Recently, RNF213 has been reported to be associated with angiogenesis. However, little is known about its endogenous function or its pathogenic role in Moyamoya disease. Our results are in line with these results and indicate that RNF213 could also be a key regulator of cerebral endothelial integrity, whose disruption could be an early pathological mechanism leading to Moyamoya disease. Dr. Negar Asdaghi:                        So, just to continue on this, there's quite a bit of research already done on association of the RNF213 gene, that's located, as we noted earlier, on chromosome 17, and basically susceptibility of development of Moyamoya disease. Can you give our listeners a brief overview of this genetic connections and what was known from past research? Dr. François Gros-Louis:               Yeah, there is a couple polymorphism describing this gene, the most frequent, the most prevalent genetic study have identified the variant R4810K, meaning for arginine is replaced by another amino acid at the position of 4810 within the protein. It's a large protein and a large gene and a susceptible gene and a risk factor for developing Moyamoya disease. Dr. François Gros-Louis:               So, people bearing this variant have a higher chance to develop the disease. This is a loss of function variant, also called inactivating mutation, meaning that the mutated gene product have less or no function. So, this variant is found in heterozygous, meaning one copy, or two copy homozygous in Moyamoya disease patients. While patient bearing homozygous mutation develop a more severe disease with earlier age of onset and worse prognosis, patients bearing heterozygous mutation can also develop the disease. Dr. François Gros-Louis:               So, strong evidence suggests that the carrying rate of RNF213 R4810K mutant is closely related and give a higher chance to develop the disease. Interestingly, also with colleagues, we found that there are other variants within this genes leading to what we think is a gain of function mutation have been associated also with other cerebrovascular disease, such as intracranial aneurysms. Dr. Negar Asdaghi:                        So, François, this is very interesting. Let me recap what you mentioned so I know that I understood it. So, this is an interesting gene, this RNF213, and basically evidence shows that mutations in the RNF213, whether it's loss of function or gain of function, both can result in variety of cerebrovascular disorders. And interestingly, the phenotype of the disease when it comes to loss of function of this gene is actually correlated with whether a person is a carrier, homozygous carrier of this gene, loss of function, or heterozygous carrier of the gene. Dr. Negar Asdaghi:                        So, very interesting information for clinicians who treat patients with Moyamoya disease, specifically those who have a family history of Moyamoya disease, so perhaps a higher chance of carrying a genetic susceptibility gene. Now, we want to get to the paper that you published in this issue of the journal, but I think before we talk about your paper, we also have to have a basic understanding of this CRISPR-Cas9 technology, which is the new genome editing technology that you use in your experiments. Can you please give us a little bit of an overview of this technology? Dr. François Gros-Louis:               Yes. CRISPR-Cas9 gene editing is genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. This technology allows genetic material to be added, removed, or altered at particular location in the genome. Several approaches to genome editing have been developed. Recent one is known as CRISPR-Cas9. So, the CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, and more accurate, and also more efficient than other existing genome editing methods. It's clearly revolutionizing the field in research. Dr. Negar Asdaghi:                        So, it's very exciting. It's truly a new chapter in gene targeting research and editing research. So, now we're ready to hear about your study. And I guess the first part of the study was just to look at how various cells in vitro that you used had expressed RNF213. Can you please tell us about the first part of your experiments? Dr. François Gros-Louis:               Yeah. We first wanted to know where the protein is expressed or where the protein is more highly expressed. So, we found by doing immunofluorescence analysis that the RNF213, so we confirmed that it's ubiquitously expressed in the cytoplasm of different cellular types. So, we found that significant difference also in the expression of RNF213 protein levels in several endothelial cells, where we found it's been highly expressed when compared to other endothelial cells isolated from different other body location, meaning outside of the CNS. So, it's highly expressed also when compared to smooth muscle cells or fibroblasts. Dr. Negar Asdaghi:                        Okay. So, just again, to recap for our listeners, this is, this RNF213 protein, is ubiquitously expressed in many different cell types, but you did find a significantly higher expression rates in endothelial cells, specifically those endothelial cells that were derived from cerebrovasculature. So, that's the first exciting part of the experiments that you showed in the study. Now, using the CRISPR-Cas9 technology, you and your team were able to successfully create an in vitro RNF213 knockout model. Can you please tell us about these models and also the main findings of your study? Dr. François Gros-Louis:               Yeah, so taken together, the results we presented in the article indicate that RNF213 could be a key regulator of cerebral, endothelial and tight junctions integrity whose disruption could be an early pathological mechanisms leading to Moyamoya disease. So, we established for the first time an easily reproducible and stable in vitro 3D model generated using the CRISPR-Cas9 gene editing technology. Dr. François Gros-Louis:               This advanced 3D culture approach has emerged as an excellent system to recapitulate histopathological feature reminiscent to disease pathogenesis. So, 3D cell culture approach is different from standard 2D culture, where cells are cultured, monolayered into a Petri dish. And we have results showing that the 3D cell culture system better mimic the in vivo conditions in terms of cell to cell and cell to matrix interaction and lead to histopathological phenotypic feature can be observed in cell culture, in a 3D fashion. Quite interestingly, alongside of providing the first evidence for the role of RNF213, the maintenance of endothelial barrier and the potential implication of this gene in the expression of maturation of tight junctions. So, we define a novel role for PECAM-1 as well in barrier impairment as a part of the disease pathogenic mechanisms. Dr. Negar Asdaghi:                        Okay. And now this is really interesting. So, I wanted to, again, recap some of the important points that you raised here. First of all, your in vitro models are different than the classic in vitro models, where 2D cells were basically grown in a Petri dish. You are trying to, more and more, replicating what happens, for instance, in blood vessels, where you have endothelial cells overlying mesenchymal cells underneath them, so tunica intima and then tunica media, and so you have 3D cells, where various types of cells are overlying each other in a more in vivo representation of what happens in blood vessels, which is truly interesting. Dr. Negar Asdaghi:                        And what you found was, in sort of summary, was that these knockout endothelial cells ended up having abnormal tight junctions and abnormal connectivity, which basically would lead in an in vivo model to abnormal leaky blood brain barrier, if this were truly in the in vivo model. Does that summarize the findings of the paper? Dr. François Gros-Louis:               Yes, perfectly. Dr. Negar Asdaghi:                        Perfect. And so I want to also give us a chance to talk about the important pro-inflammatory aspects of these knockout cells. You did find that a number of cytokines were expressed in excess in those RNF213 deficient cells. Can you please elaborate on those findings? Dr. François Gros-Louis:               So, to further investigate whether inflammation plays an important role in RNF213-associated Moyamoya disease development, we indeed performed experiments to study pro-inflammatory cytokines and analyze the immune secretome profiles of cerebral RNF213 deficient endothelial cells. So, then the cells can secrete different cytokines or different other proteins. So, by analyzing the secretome, we found an end secretion of a few pro-inflammatory cytokines indicating that inflammation may also play a central role in the initiation of the immune response in the pathogenesis of the disease. Dr. Negar Asdaghi:                        So, this is exciting, François. For years, we thought about the pathophysiology of Moyamoya disease as a disorder involving large vessels. And perhaps the initial thought was that it starts with excessive proliferation of smooth muscles within the middle layer of the cerebral blood vessels, in tunica media, and then perhaps subsequently there will be other abnormalities, including the intimal hyperplasia that is classically seen in Moyamoya. Dr. Negar Asdaghi:                        Your study seems to propose a shift in that pathophysiological paradigm, where the problem seems to start from endothelial cells, so inside of the blood vessels and the tunica intima, and then gradually would go out to the middle layers, and, of course, proposes the hyperinflammatory state in the Moyamoya disease as well. So truly interesting. Do you think that that is the new or rather a paradigm shift for pathophysiology of MMD? Dr. François Gros-Louis:               That's a great question. Our results certainly demonstrated that endothelial cells are involving in the disease pathogenesis in Moyamoya disease, but it doesn't exclude the possibility that other cell types might also be involved in the disease pathogenesis. We know, like you mentioned, that a blood vessel is formed by two different cell layers, tunica intima, media, and adventitia, containing, respectively, endothelial cells, smooth muscle cells, and fibroblasts. So which cells are to be blamed in Moyamoya disease is a question of many ongoing results studies over the years. Dr. François Gros-Louis:               So, using tissue-engineered approach to reconstruct small caliber blood vessels, as we developed in my lab, in combination with patient-derived stem cells, in which adult cells isolated from a patient of any individuals can be reprogrammed into stem cells and re-differentiated into different cell types in occurrence, smooth muscle, fibroblasts, or endothelial cells. We would like to generate blood vessels in which each of the different cellular layers will harbor or not, or a combination with RNF213 mutants. So, this will hopefully help us to elucidate this question. Dr. Negar Asdaghi:                        That's perfect. So, François, before we end the interview, I wanted to ask two more questions. So, what should be our top two takeaway messages from your study? Dr. François Gros-Louis:               We believe that the innovative transdisciplinary approach to generate, for the first time, as we describe in the article, an in vitro 3D model recapitulating important diseases features. So, this model could become a unique tool in precision medicine to study Moyamoya disease or other RNF213-associated pathologies. So, our study provides, for the first time, role of RNF213 in the maintenance of blood-brain barrier and the potential implication of RNF213 in the expression and maturation of tight junctions. Taken together, our data define a novel role for PECAM-1 in the blood-brain barrier impairment in Moyamoya disease. Dr. François Gros-Louis:               So, better characterization of each, also this regulated inflammatory molecules, we found taken separately could reveal a crucial information and help elaborate a more precise approach. Hence, this pro-inflammatory signature could be used as a circulatory biomarker for the follow-up of Moyamoya disease patients and to manage an appropriate treatment, according to the pathology progression. Dr. Negar Asdaghi:                        François, this is great. And last, I want to digress a little bit and ask you about the future of gene editing. I think it's important to end our interview with a little bit of a discussion regarding the future of CRISPR-Cas9 technology. In subatomic quantum physics, people talk about the God particles. And I feel that the CRISPR-Cas9 technology is, in a way, like playing God, if you agree. What do you think is the future for gene editing, and how do you see that helping us in terms of treatment of genetic causes of cerebrovascular disorders? Dr. François Gros-Louis:               Yes, gene editing is, like I said, revolutionizing, of course, experimental therapies for genetic disorder and generated excitement for new and improved gene therapies. We can think that it will be possible to correct any gene mutations associated with a disease to reestablish the normal or natural gene function and help treating the targeted diseases. But also, to me, the future of genome editing also resides in optimizing next generation disease models. The use of genome editing, in particular, the CRISPR-Cas9 technology, has extended to potential in generating new personalized model for a number of disorder, not only including Moyamoya disease or other cerebrovascular diseases, but also diseases like Alzheimer's, ALS, or Parkinson's disease, for which obtaining patient sample is difficult. Dr. François Gros-Louis:               No one wants to give up a bit of his brain. So modeling it, this disease, in vitro will be really helpful in combination also gene editing with the stem cells, induced pluripotent stem cells technology, will allow the generation of better model to mimic human disease and reflects the genetic drivers that govern specific pathology. So, the synergy between IPS cell-based model system and gene editing will play a pivotal role in the root of precision medicine and clinical translation in the future. Dr. Negar Asdaghi:                        Dr. François Gros-Louis, it was a pleasure learning from you. And we look forward to the endless possibilities brought by the future of genome editing technology. Dr. François Gros-Louis:               It was a pleasure discussing with you. Dr. Negar Asdaghi:                        Thank you for joining us. Dr. Negar Asdaghi:                        And this concludes our podcast for the April 2022 issue of Stroke. Please be sure to check out this month's table of contents for the full list of publications, including a series of Focused Updates on the topic of blood pressure management in stroke, organized by Dr. Else Sandset. I would also like to draw your attention to two scientific statements from the American Heart Association, which appear in print in the April issue. The first one is titled "Identifying Best Practices to Improve Evaluation and Management of In-Hospital Stroke," and the second one is on the effect of marijuana use on brain health. Dr. Negar Asdaghi:                        And now, to end our podcast, last month, in honor of the 2022 Olympic Games, and to celebrate those with determination to survive and push despite the most difficult of circumstances, we ended our podcast with the story of a refugee Olympic athlete. Dr. Negar Asdaghi:                        Sadly, since our last podcast, the world has seen even darker days of war, mass immigration, displacement, and human suffering. At times like this, we're reminded that although not all of us can help everyone, but at least each of us can do something to help someone, and the comfort in knowing that what we do in the field of medicine, from daily patient care to the scientific work leading to the next medical breakthrough, every action is a step forward in reducing the suffering of another person. And what better way to do this than staying alert with Stroke Alert. Dr. Negar Asdaghi:         This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.

Calling all budding entrepreneurs, today's bonus episode is for you! We often hear from the founders and CEOs from the U.S., but how different is it to start and find funding for your startup in Canada? The answer to that and so much more is covered in today's episode. Joining me on the podcast is the co-founder & CEO of oxio, a Canadian home internet provider that offers fair and affordable pricing (and the one I currently use for my internet in case you're wondering).  Marc-André Campagna is from Baie-Comeau, Quebec and as I mentioned is the CEO and co-founder of oxio. After helping his parents move and set up their internet, it sparked his interest in developing a more affordable internet provider that put Canadians' needs first. This led him to drop out of Law School at Laval University to start Accès Télécom (now oxio) along with his friend Francis Careau. In this episode, Marc-André shares what it was like to launch a successful startup in Canada including finding investors, participating in an incubator program, and understanding the importance of networking. He also explains how oxio is shaking things up in the telecom industry by putting the customer experience first and why Canada needs to move away from oligopolies. For full episode show notes visit: https://jessicamoorhouse.com/324

Episode 170: James Eaves, Ph.D., is an agricultural economist and professor at Laval University. His research focuses on how emerging technology can improve the profitability and sustainability of controlled-environment agriculture. He is also the Director of Indoor Agriculture at VoltServer and formally the Head of R&D at Greenseal Cannabis company. https://www.linkedin.com/in/jameseaves/

The rule of thumb…many have experienced the uncomfortable sensation of pain at the base of their thumb at some point in life, especially therapists! Let's learn from Mirka Normand, out of Connecticut, to unpack the multitude of factors that lead to CMC arthritis. Learn how to address it from our evaluation strategies to treatment and splinting options. Mirka Normand graduated with a Bachelor of Science in Occupational Therapy from Laval University in Québec, Canada. She completed a Hand Therapy Fellowship with Baylor College of Medicine and Texas Woman's University in 1999, in Houston TX and was certified as a hand therapist that same year by the Hand Therapy Certification Commission. She received her Advanced Master's degree with hand therapy emphasis in 2003 from Texas Woman's University. She was certified as an orthopedic manual therapist through The International Academy of Orthopedic Medicine-US (IAOM-US) in 2006, and soon after joined their faculty for the creation of a specialty Hand and Upper Extremity Track. Mirka works full time as a clinician for Yale New Haven Health System-L&M Hospital on the eastern coast of Connecticut, and lectures nationally for IAOM-US. She is known through Medbridge with instruction on the wrist. She recently submitted her synthesis for her PhD. And will be defending this in the near future, after many months in the lab and reading research. Congratulations to Mirka on these accomplishments. DeMott, L. (2017). Novel isometric exercises for the dynamic stability programs for thumb carpal metacarpal joint instability. Journal of Hand Therapy,  30, 372-375. http://dx.doi.org/10.1016/j.jht.2016.09.005 Book: Albrecht, Jan OTR/L, CHT (2004). Caring for the Painful Thumb, More Than a Splint. 1st ed.  North Mankato, Minn. ISBN: 0-976117-0-X

Subscribe to Renata's weekly newsletter for exclusive content for corporate professionals and new episodes of the Job Hunting Podcast. About our guests: Carly Moulang is an Associate Professor in Accounting at Monash University with over 20 years of experience in Higher Education. She holds a Ph.D. in management accounting and a Graduate Diploma in Psychology from Monash University. She is a CPA Australia member and a Chartered Accountant (CA ANZ). Carly's research agenda incorporates psychological research within the accounting and finance disciplines. Her multi-disciplinary research has included topics such as whistleblowing, creativity, performance management, environmental management accounting, wellbeing, and psychological capital, superannuation research, and decision-making. Carly's research has been widely disseminated via television, documentaries, podcasts, radio interviews, and news articles. Her work broadly contributes towards achieving better retirement, performance, and mental health outcomes for women. You can connect to Carly via LinkedIn.  Alessandro Ghio is an Assistant Professor in Accounting at Laval University (Quebec, Canada). He holds a Ph.D. in financial accounting from ESSEC Business School and a Ph.D. in management from the University of Pisa. His research interests focus on the sociology of professions, in particular about issues concerning women and queer people in the accounting profession. His work contributes to the understanding of how accounting phenomena emerge and evolve in a social context and the mechanisms affecting such processes. Alessandro has published in several leading academic journals and he co-authored three books. Alessandro received the prestigious 2019 Aspen Institute ‘Ideas Worth Teaching' Award and the 2019 Vice-Chancellor's Diversity and Inclusion Award. He is the co-instigator of the project “Queering Accounting” and he has led and/or taken key roles in competitive research-funded projects equating to over one million Australian dollars. Prior to joining Laval University, Alessandro has been a Lecturer at Monash University, a controller in a large telecommunication organization, a consultant for the Italian Ministry of Education on social mobility in education, and a visiting scholar at Indiana University (USA). You can connect with Alessandro via LinkedIn. Carly and Alessandro's research website: https://www.workingwomenandwellbeing.com/   Episode Timestamps: 04:48 - Carly's career 06:11 - Alessandro's career 07:23 - Researching gender issues in the workplace 10:44 - Research findings 18:04 - Minorities in the workplace 21:12 - Recommendations for employers 30:42 - Recommendations for women and minorities 48:23 - Final words from Carly and Alessandro Links mentioned in this episode: Sign up for Renata's newsletter Renata's article on LinkedIn: Pitfalls of corporate ‘small talk': embracing diversity also means including new themes in our repertoire! The Job Hunting Podcast episodes on women's issues in the workplace: With Div Pillay With Michelle Redfern With Sonali Shah With Susan Colantuono The Job Hunting Podcast episode on job hunting and career progression for the trans, gender diverse, and nonbinary professionals - with Jacob Thomas Other ways to enjoy this podcast: Read the full blog on the podcast website Download a transcript of this episode Are you new to The Job Hunting Podcast? If so, here is a bit about your host: Hello, I'm Renata Bernarde, the Host of The Job Hunting Podcast. I'm also an executive coach, job hunting expert, and career strategist. I teach corporate, non-profit, and public professionals the steps and frameworks to help them find great jobs, change, and advance their careers with confidence and less stress.  If you are 1) an ambitious professional who is keen to develop a robust career plan, 2) looking to find your next job or promotion, or 3) you want to keep a finger on the pulse of the job market so that when you are ready, and an opportunity arises, you can hit the ground running – then this podcast is for you. In addition to The Job Hunting Podcast, I have developed a range of courses and services for professionals in career or job transition. And, of course, I also coach private clients.  So there is no excuse – I'm determined to help you! I want you to feel empowered, nail your next job, and have the career you want. Subscribe to the newsletter and access free tools to help you advance in your career. A free resource for job hunters: The Optimized Job Search Schedule. Learn more: www.renatabernarde.com. Book a time to discuss 1-1 coaching and achieve your goals faster Or please email me at rb@renatabernarde.com.       Please support The Job Hunting Podcast: Follow, subscribe, share, rate, and review: Thank you so much again for listening to the episode. If you enjoyed the content, please leave us a review and give it a 5-star rating on your podcast platform of choice. A review is the best gift you can give to a podcaster; I'll be so happy you wouldn't believe it! Writing a review and giving it five stars helps the podcast reach more people like you who want guidance and support in job hunting and career advancement. Enjoy the episode and ciao for now! RB Renata Bernarde | Job Hunting Expert | Founder, Pantala Academy Book a time to discuss 1-1 coaching and achieve your goals faster rb@renatabernarde.com      www.renatabernarde.com   --------- Host: Renata Bernarde Editing: Estella Dacuba Music: Scott Holmes Contact us: rb@renatabernarde.com The Job Hunting Podcast is a podcast by Pantala Pty Ltd. Pantala acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Bunurong People. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures.